Insulet v EOFlow: $452M Trade Secret Verdict Reversed
Following a high-stakes, five-week federal trial, a Massachusetts jury originally handed Insulet Corporation a massive victory, finding that South Korean rival EOFlow Co. had willfully and maliciously misappropriated core trade secrets—including CAD files, manufacturing processes, and algorithms—to clone Insulet's Omnipod insulin pump system. Though the district Court heavily reduced the initial $452 million verdict down to a finalized $59.4 million judgment coupled with a permanent worldwide sales injunction, the legal tide completely turned on appeal. On May 28, 2026, the U.S. Court of Appeals for the Federal Circuit completely reversed the liability judgment and vacated the damages and injunction. The appellate Court ruled that the jury's findings on the statute of limitations lacked substantial evidence, determining that Insulet possessed enough public information regarding EOFlow's hiring of its former engineers and subsequent product similarities to file a claim long before the critical August 2020 statutory deadline.
